Published • loading... • Updated
Full-Life Technologies Announces US$150 Million Financing to Accelerate Multiple Clinical Stage Assets and Manufacturing Capabilities
The round includes about $110 million in Series D equity and $40 million in debt to advance lead cancer programs and Belgium manufacturing.
- On Monday, May 18, 2026, Full-Life Technologies announced completion of a $150 million financing package comprising $110 million in Series D equity and $40 million in debt financing.
- Proceeds will advance clinical stage assets including FL-020 and FL-261, while ensuring the Belgium GMP facility is fully operational to support global 225Ac commercial supply.
- Vivo Capital led the financing round, with Managing Director Hao Dong praising Full-Life's "ability to translate it into tangible clinical and operational milestones" at global scale.
- President and Chief Financial Officer Julie Wu noted the financing reflects value created over four years, bringing total funding to nearly $350 million since Full-Life's 2021 inception.
- By year-end 2026, Full-Life expects three differentiated clinical-stage programs from its UniRDC discovery platform, leveraging its "Ecosystem Strategy" to deliver strategic support beyond capital.
Insights by Ground AI
38 Articles
38 Articles
keenesentinel.com+37 Reposted by 37 other sources
Full-Life Technologies Announces US$150 Million Financing to Accelerate Multiple Clinical Stage Assets and Manufacturing Capabilities
SUZHOU, China and GEMBLOUX, Belgium, May 18, 2026 /PRNewswire/ -- Full-Life Technologies ("Full-Life", the "Company"), a fully-integrated global radiotherapeutics company, today announced the completion of a US$150 million financing package, comprised of approximately US$110 million in Series D equity and…
Coverage Details
Total News Sources38
Leaning Left3Leaning Right3Center15Last UpdatedBias Distribution72% Center
Bias Distribution
- 72% of the sources are Center
72% Center
14%
C 72%
14%
Factuality
To view factuality data please Upgrade to Premium
